Saltar al contenido
Merck
Todas las fotos(2)

Documentos

85256

Supelco

Tamoxifeno

analytical standard

Sinónimos:

(Z)-1-(p-Dimetilaminoetoxifenil)-1,2-difenil-1-buteno, trans-2-[4-(1,2-Difenil-1-butenil)fenoxi]-N,N-dimetiletilamina

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Fórmula lineal:
C6H5C(C2H5)=C(C6H5)C6H4OCH2CH2N(CH3)2
Número de CAS:
10540-29-1
Peso molecular:
371.51
EC Number:
234-118-0
MDL number:
MFCD00010454
UNSPSC Code:
41116107
PubChem Substance ID:
329769367
NACRES:
NA.24

grade

analytical standard

Quality Level

100

assay

≥98.0% (HPLC)

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

impurities

≤0.5% water

mp

97-98 °C (lit.)

application(s)

forensics and toxicology
pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC\C(c1ccccc1)=C(/c2ccccc2)c3ccc(OCCN(C)C)cc3

InChI

1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-

InChI key

NKANXQFJJICGDU-QPLCGJKRSA-N

Gene Information

human ... ESR1(2099)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Biochem/physiol Actions

Inhibidor de la proteína cinasa C. Induce apoptosis en las líneas celulares de glioma maligno humano. El tamoxifeno y su metabolito el 4-hidroxitamoxifeno son modificadores selectivos de la respuesta a los estrógenos (SERM) que actúan como antagonistas de los estrógenos en las glándulas mamarias. Bloquea la producción del VEGF estimulada por estradiol en las células tumorales de mama.

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Danger

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificados de análisis (COA)

Lot/Batch Number
BCCG8921
BCCC8810
BCCB8695
BCBW6527
BCBV2433

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Jack Cuzick et al.
The Lancet. Oncology, 16(1), 67-75 (2014-12-17)
Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy women at increased risk of breast cancer in the first 10 years of follow-up. We report the long-term follow-up of the
L Binkhorst et al.
Clinical pharmacology and therapeutics, 92(4), 431-433 (2012-08-23)
Traditionally, all patients treated with tamoxifen receive a standard dose. A number of studies claimed a clinically relevant impact of cytochrome P450 2D6 (CYP2D6) genotype on outcome, and therefore genotyping before tamoxifen therapy was advocated. Recent data showed that adequate
Takeo Nakaya et al.
Cancer research, 74(10), 2882-2891 (2014-03-15)
The intestinal epithelium maintains homeostasis by a self-renewal process involving resident stem cells, including Lgr5(+) crypt-base columnar cells, but core mechanisms and their contributions to intestinal cancer are not fully defined. In this study, we examined a hypothesized role for
Karin Beelen et al.
Breast cancer research : BCR, 16(1), R13-R13 (2014-01-29)
Inhibitors of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway can overcome endocrine resistance in estrogen receptor (ER) α-positive breast cancer, but companion diagnostics indicating PI3K/AKT/mTOR activation and consequently endocrine resistance are lacking. PIK3CA mutations frequently occur in ERα-positive
Wataru Ise et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(32), 11792-11797 (2014-07-30)
In primary humoral responses, B-cell lymphoma 6 (Bcl6) is a master regulator of follicular helper T (TFH) cell differentiation; however, its activation mechanisms and role in memory responses remain unclear. Here we demonstrate that survival of CXCR5(+) TFH memory cells
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico